Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
- Author:
Ji-yin ZHOU
1
;
Shi-wen ZHOU
Author Information
1. Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University of PLA, Chongqing 400037, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Berberine;
pharmacology;
Diabetes Mellitus, Experimental;
metabolism;
Diabetes Mellitus, Type 2;
metabolism;
Diabetic Retinopathy;
metabolism;
Fenofibrate;
pharmacology;
Hypoglycemic Agents;
pharmacology;
Male;
PPAR alpha;
metabolism;
PPAR delta;
metabolism;
PPAR gamma;
metabolism;
Rats;
Rats, Wistar;
Retina;
metabolism;
pathology;
Thiazolidinediones;
pharmacology
- From:
Acta Pharmaceutica Sinica
2007;42(12):1243-1249
- CountryChina
- Language:English
-
Abstract:
Retinopathy is a major cause of morbidity in diabetes and remains the primary cause of new blindness. Therefore, it is necessary to find new drug to treat diabetic retinopathy. Type 2 diabetes mellitus (T2DM) rats were induced by injection (ip) with streptozotocin (STZ) 35 mg x kg(-1) and fed with a high-carbohydrate/high-fat diet 2 weeks later. From week 17 to 32, diabetic rats were given different doses of berberine 75, 150, and 300 mg x kg(-1), fenofibrate 100 mg x kg(-1) and rosiglitazone 4 mg x kg(-1), separately. Retinal structure was observed with hematoxylin-eosin staining and peroxisome proliferator-activated receptors (PPARs) alpha/delta/gamma protein expressions were detected by immunohistochemistry. The retina of control rats was thicker than that of other groups, 16 weeks treatment with berberine (150 and 300 mg x kg(-1)) and rosiglitazone 4 mg x kg(-1) thickened the diabetic retina, but no difference existed in retinal structure among groups. Both berberine (150 and 300 mg x kg(-1)) and rosiglitazone 4 mg x kg(-1) significantly decreased PPARy expression in diabetic retina; while berberine (150 and 300 mg x kg(-1)) and fenofibrate 100 mg x kg(-1) obviously increased both PPARalpha and PPARdelta expressions in diabetic retina. Berberine modulates PPARalpha/delta/gamma protein levels in diabetic retina which may contribute to ameliorate retinopathy complication induced by STZ and a high-carbohydrate/high-fat diet. It is expected that berberine might be a more beneficial drug to treat diabetic retinal complication comparing with fenofibrate and rosiglitazone.
